Phase II trial of PM 01183 as second-line therapy in patients with metastatic pancreatic cancer

Trial Profile

Phase II trial of PM 01183 as second-line therapy in patients with metastatic pancreatic cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Pancreatic cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
    • 07 Apr 2014 Results from a retrospective study conducted using data from this trial have been presented at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) according to a PharmaMar media release.
    • 10 Mar 2012 Planned end date 5 Feb 2014 added as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top